News

RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM

Posted by RadioMedix Marketing on

RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors First Targeted Alpha Therapy to receive a Breakthrough Therapy Designation February 12, 2024 04:32 AM Eastern Standard Time HOUSTON & PARIS RadioMedix, Inc. and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to AlphaMedixTM (212Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who are naïve to peptide receptor radionuclide therapy (PRRT). AlphaMedixTM is a Targeted Alpha Therapy currently in Phase 2...

Read more →

RadioMedix Inc. Acquisition of its 225Ac-PSMA I&T, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer

Posted by RadioMedix Marketing on

RadioMedix Inc. Acquisition of its 225Ac-PSMA I&T, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer

RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc. Houston, TX, Feb. 15, 2023  RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage radiopharmaceutical company announced the acquisition of it’s 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals. Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.  225Ac-PSMA-I&T is currently being evaluated under a phase 2 physician-sponsored investigational new drug (IND) under the acronym of TATCIST trial. RadioMedix will also provide manufacturing support to Fusion for the TATCIST trial and first pivotal clinical trial...

Read more →

RadioMedix and Vect-Horus announce first dosing of GBM and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH

Posted by RadioMedix Marketing on

Houston, TX, USA and Marseille, France, Nov. 15, 2022  RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC). This radiotracer will serve as a companion diagnostic for future Targeted Alpha Therapy (TAT) for these cancers. 68Ga-RMX-VH is a positron-emitting tomography (PET) agent that targets the Low-Density Lipoprotein Receptor (LDLR) overexpressed in some solid tumors such as GBM and PDAC. The objective of this exploratory study is to evaluate the safety, dosimetry, and bio-distribution...

Read more →

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

Posted by RadioMedix Marketing on

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers Trial’s Objective Response Rate Endpoint Already Achieved May 16, 2023 02:00 AM Eastern Daylight Time HOUSTON & PARIS RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the last patient has been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE (AlphaMedix™). This trial is being conducted to evaluate the safety and effectiveness of AlphaMedix™ in peptide receptor radionuclide therapy (PRRT) of naive patients with somatostatin receptor-expressing neuroendocrine tumors (NET), regardless of the location of the...

Read more →

RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy

Posted by RadioMedix Marketing on

RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy

  RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology. Michael Lee-Chin appointed to the board of the company.     Houston, Texas and Burlington, Ontario, October 6th, 2022 – RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage biotechnology company announced the arrangement with Portland Investment Counsel Inc. (“Portland”) to complete an equity round of $40 million of a Series A funding round. Radiomedix is committed to the advancement of a targeted alpha therapy (TAT) pipeline and diagnostic companion radiopharmaceuticals for rare and...

Read more →